AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

STC-1 for the Treatment of Eye Diseases

Technology Benefits

- Naturally occurring protein- Rescues photoreceptor degeneration in two rat models of RD

Technology Application

Ophthalmology: Dry (atrophic) age-related macular degeneration (AMD) and Retinitis Pigmentosa

Detailed Technology Description

This technology is based on the finding that mesenchymal stem cells can be activated by signals from cells undergoing programmed cell death (apoptosis) to reduce the programmed cell death by secretion of stanniocalcin-1 (STC-1). STC-1 protein was originally identified as a calcium/phosphate regulatory protein in fish, but the mammalian STC-1 protein was found to have multiple effects including protection against ischemia and reduction of inflammatory responses. Intravitreal eye injections of STC-1 have been found to rescue photoreceptors (rods and cones) from degeneration in two different rat models of RD. Stanniocalcin therapy thus represents a promising therapy for diseases associated with photoreceptor cell loss, including dry AMD and RP. Currently, research is being conducted to determine effectiveness of STC-1 in transgenic pig models.

Country/Region

USA

For more information, please click Here